Medicinova/ US58468P2065 /
| 2024-04-30 8:56:49 PM | Chg. -0.03 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 1.28USD | -1.92% | 104 Turnover: 135.12 |
-Bid Size: - | -Ask Size: - | 1.30 | 1.28 |
GlobeNewswire
04-03
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Gliobla...
GlobeNewswire
03-27
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treat...
GlobeNewswire
03-21
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentatio...
GlobeNewswire
03-12
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung I...
GlobeNewswire
01-17
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment...
GlobeNewswire
2023-12-22
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accep...
GlobeNewswire
2023-12-07
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for t...
GlobeNewswire
2023-11-20
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Gliob...
GlobeNewswire
2023-10-27
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment...
GlobeNewswire
2023-10-11
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudi...
GlobeNewswire
2023-09-28
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medi...
GlobeNewswire
2023-08-18
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation...
GlobeNewswire
2023-08-17
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for ...
GlobeNewswire
2023-08-16
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Scler...
GlobeNewswire
2022-03-17
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment ...
GlobeNewswire
2022-03-15
MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hos...
GlobeNewswire
2022-02-28
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treat...
GlobeNewswire
2022-02-22
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Diso...
GlobeNewswire
2022-01-31
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ba...
GlobeNewswire
2022-01-27
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for ...
GlobeNewswire
2022-01-26
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for H...
